Symbols

JBIO

Jade Biosciences·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About JBIO

Jade Biosciences, Inc.

A biotechnology company dedicated to developing transformative therapies for autoimmune diseases

Industry

Pharmaceutical

Established Date

07/27/2018

Listing Date

06/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.jadebiosciences.com

Security Type

Common stock

Office address

221 Crescent Street, Building 23, Suite 105, Waltham, Massachusetts 02453

Business

Introduction

Jade Biosciences, Inc., was originally incorporated on July 27, 2018 as Aerovate Therapeutics, Inc., a Delaware-based company. After completing the merger and change of registration in April 2025, the company is now a Nevada company focused on the development of novel biological therapies for patients with autoimmune diseases. Its lead drug candidate, JADE101, targets APRIL for the treatment of IgA nephropathy, and also targets BAFF-R and other undisclosed pathways.

Company Financials

EPS

JBIO has released its 2025 Q4 earnings. EPS was reported at 10.25, versus the expected -0.48, beating expectations. The chart below visualizes how JBIO has performed over recent quarters, highlighting trends in earnings surprises.